Reducing Off-Target Accumulation of Chemotherapeutic Nanomedicines

Summary

This research project investigates a novel approach to reduce off-target accumulation of chemotherapeutic nanomedicines in healthy tissues by exploiting an innate immune response, thereby improving chemotherapy efficacy and reducing toxicity.

What they want

The project will characterize the IFN-λ-mediated epithelial tightening response in terms of dose, route of administration, timing, and its effects on organ and skin toxicity. Experiments will identify conditions to minimize adverse effects of chemotherapy while enhancing drug accumulation in tumors. The research will also explore aggressive chemotherapy dosing in two syngeneic mouse models for ovarian cancer and conduct immune profiling to assess synergistic effects of IFN-λ with Doxil.

Deliverables

Characterization of the IFN-λ-mediated tightening response
Identification of conditions to minimize chemotherapy adverse effects and enhance tumor drug accumulation
Assessment of synergistic effects of IFN-λ with Doxil in ovarian cancer mouse models

Technical requirements

Utilization of virus-like particles (lipoplexes)
Pretreatment with IFN-λ cytokine
Use of tumor-bearing mice
Application of liposomal doxorubicin (Doxil®)
Characterization of IFN-λ dose, route of administration, and timing
Assessment of organ and skin toxicity
Use of two syngeneic mouse models for ovarian cancer
Immune profiling

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.